Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.75 |
| ▸ | GLA | P06280 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | HPGD | P15428 | 3/20 | 0.73 |
| ▸ | GAA | P10253 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.65 |
| ▸ | USP2 | O75604 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301153 | 0.94 | CSNK2A1 (0.73) | KDM4EGLAALDH1A1HPGDGAA | |
| SCHEMBL15210094 | 0.94 | KDM4E (0.68) | KDM4EGLAALDH1A1HPGDGAA | |
| SCHEMBL297362 | 0.94 | KDM4E (0.72) | KDM4EGLAALDH1A1HPGDGAA | |
| SCHEMBL300813 | 0.92 | KDM4E (0.74) | KDM4EGLAALDH1A1HPGDGAA | |
| SCHEMBL300825 | 0.89 | KDM4E (0.82) | KDM4EGLAALDH1A1HPGDGAA | |
| SCHEMBL300901 | 0.89 | KDM4E (0.73) | KDM4EGLAALDH1A1HPGDGAA | |
| SCHEMBL297473 | 0.89 | KDM4E (0.73) | KDM4EGLAALDH1A1HPGDGAA | |
| SCHEMBL298073 | 0.88 | KDM4E (0.70) | KDM4EGLAALDH1A1HPGDGAA | |
| SCHEMBL1750398 | 0.88 | KDM4E (0.70) | KDM4EGLAALDH1A1HPGDGAA | |
| SCHEMBL301261 | 0.88 | KDM4E (0.70) | KDM4EGLAALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078018-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2012-03-14 | — | — | EP | claimed |
| US-11166950-B2 | Treatment of cancer with TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-11-09 | — | — | US | disclosed |
| CN-107976546-B | Inhibition of phosphorylation of TOR kinase inhibitory Activity markers PRAS40, GSK 3-beta, or P70S6K1 | 西格诺药品有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-110721186-A | Treatment of prostate cancer with TOR kinase inhibitors | 西格诺药品有限公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-107157990-B | Treatment of cancer with TOR kinase inhibitors | 西格诺药品有限公司 | 2020-01-07 | — | — | CN | disclosed |
| CN-109846884-A | With TOR kinase inhibitor for treating cancer | 西格诺药品有限公司 | 2019-06-07 | — | — | CN | disclosed |
| US-20180235960-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2018-08-23 | — | — | US | disclosed |
| US-9937170-B2 | Treatment of cancer with TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170027932-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9555033-B2 | Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9493466-B2 | Treatment of cancer with TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-11-15 | — | — | US | disclosed |
| CN-104271139-A | Treatment of cancer with tor kinase inhibitors | SIGNAL PHARM LLC | 2015-01-07 | — | — | CN | disclosed |
| CN-104271138-A | Treatment of cancer with tor kinase inhibitors | SIGNAL PHARM LLC | 2015-01-07 | — | — | CN | disclosed |
| US-20140113904-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130245026-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245027-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130102613-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | US | disclosed |
| CN-102821767-A | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARM LLC | 2012-12-12 | — | — | CN | disclosed |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245027-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, BRCA1 | KDM4E 1384/4885GLA 2565/4885ALDH1A1 4555/4885 |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | STK11, STK16, STK10 | KDM4E 3306/4885GLA 3236/4885ALDH1A1 3059/4885 |
| US-20170027932-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | KDM4E 877/4885GLA 3723/4885ALDH1A1 4675/4885 |
| US-20130245026-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, CHEK2, CHEK1 | KDM4E 2384/4885GLA 2713/4885ALDH1A1 4280/4885 |
| US-20180235960-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | KDM4E 877/4885GLA 3723/4885ALDH1A1 4675/4885 |
| US-20130102613-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | KDM4E 877/4885GLA 3723/4885ALDH1A1 4675/4885 |
| US-20140113904-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, TNNI3K | KDM4E 1874/4885GLA 2002/4885ALDH1A1 4005/4885 |
| US-11166950-B2 | Treatment of cancer with TOR kinase inhibitors | MTOR, TTK, RICTOR | KDM4E 877/4885GLA 3723/4885ALDH1A1 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.